China (Mainland)
Peptide Apis Bivalirudin /Bivalirudin Trifluoroacetate CAS NO.128270-60-0
- Min.Order: 1 Gram
- Payment Terms: T/T,
- Product Details
Keywords
- Bivalirudin supplier, peptide api
- Bivalirudin Trifluoroacetate
- Bivalirudin ,research peptide
Quick Details
- ProName: Peptide Apis Bivalirudin /Bivalirudin ...
- CasNo: 128270-60-0
- Molecular Formula: C98H138N24O33
- Appearance: White powder
- Application: pharmaceutical ingredients ,research c...
- DeliveryTime: Within 3-5days
- PackAge: According client's requirements
- Port: shanghai
- ProductionCapacity: 10000 Gram/Month
- Purity: 98% Min
- Storage: keep sealed and keep from direct light
- LimitNum: 1 Gram
- Moisture Content: NML 7%
- Impurity: NML2.0%
Superiority
Our Advantages:
1.Product Capacity: eptidego has produced thousands of peptides ranging in quantity from milligrams to multiple kilograms with purities up to 99.0%.
2. Samples free trial: our company welcome samples to test our quality then make regular orders.
3. Good Service: the company have 24 hours online service and feedback to our clients ontime
4. Quality guarantee: We have strict quality control system before our delivery and refunds or re-deliver if any quality problems.
5. Fast Delivery and safe shipping: The compnay process orders in time and have much experienced in internation shipping, always keep goods safe shipping and fast delivery.
Details
Product Name: Bivalirudin Trifluoroacetate
Synonyms: BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;Bivalirudin, TFA;BITTERMELONP.E;Human Bivalirudin;Bivalirudin Acetate;Bivalirudin BG 8967, Hirulog, Hirulog I;BG 8967, Hirulog, Hirulog I
CAS: 128270-60-0
MF: C98H138N24O33
MW: 2180.29
Product Categories: Peptide;API;proteins
Purity: 99%,
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin.It inhibits both circulating and clot-bound thrombin,while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life.It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).It does not require a binding cofactor such as antithrombin and does not activate platelets.These characteristics make bivalirudin an ideal alternative to heparin.
